CDKL3: A Potential Drug Target and Biomarker for Cancer (G51265)

Target Name: CDKL3

NCBI ID: G51265

CDKL3

CDKL3: A Potential Drug Target and Biomarker for Cancer

Introduction

Cyclin dependent kinase like 3 (CDKL3) is a protein that plays a crucial role in cell cycle regulation, which is a critical process for the growth, division, and survival of cells. CDKL3 is a key regulator of the G1 phase, which is a critical stage of the cell cycle where cell growth and repair occur. CDKL3 functions by phosphorylated tubulin, which is a protein that helps maintain the integrity of microtubules in the cytosol.

CDKL3 is a protein that has been identified as a potential drug target and biomarker for cancer. Its unique mechanism of action and its involvement in the regulation of cell cycle have make it an attractive target for drug development. In this article, we will explore the biology of CDKL3 and its potential as a drug target and biomarker for cancer.

Biomarker Potential

CDKL3 has been shown to be involved in the regulation of cancer cell proliferation. It has been shown to promote the growth and survival of cancer cells by inhibiting the inhibition of cell growth factors. CDKL3 has also been shown to play a role in the development of cancer by promoting the formation of cancer stem cells.

Drug Target Potential

CDKL3 is a protein that has been shown to be involved in the regulation of many cellular processes, including cell growth, cell cycle, and DNA replication. Its unique mechanism of action and its involvement in the regulation of cell cycle have make it an attractive target for drug development.

CDKL3 has been shown to play a role in the regulation of the G1 phase of the cell cycle. It does this by phosphoizing microtubules and interacting with the protein T-cell kinase (TCK). This interaction between CDKL3 and TCK has been shown to play a role in the regulation of cell cycle progression.

CDKL3 has also been shown to play a role in the regulation of DNA replication. It does this by interacting with the protein DNAA1 and promoting the formation of double-stranded DNA. This interaction between CDKL3 and DNAA1 has been shown to play a role in the regulation of DNA replication and the risk of cancer.

In addition to its involvement in the regulation of cell cycle and DNA replication, CDKL3 has also been shown to play a role in the regulation of cell survival. It does this by promoting the formation of cancer stem cells, which are cells that have the ability to differentiate into any cell type in the body. This interaction between CDKL3 and cancer stem cells has been shown to play a role in the development of cancer.

Conclusion

CDKL3 is a protein that has been shown to play a crucial role in the regulation of cell cycle and many cellular processes. Its unique mechanism of action and its involvement in the regulation of cell cycle have make it an attractive target for drug development. The potential of CDKL3 as a drug target and biomarker for cancer makes it an important area of 鈥嬧?媟esearch. Further studies are needed to fully understand the biology of CDKL3 and its potential as a drug target and biomarker for cancer.

Protein Name: Cyclin Dependent Kinase Like 3

The "CDKL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDKL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets